Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of maridebart cafraglutide in obesity or overweight
2026-525408-82-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Maridebart cafraglutide with Placebo (2 arms). Primary endpoints: Percent change from baseline of the parent trial in body weight and Incidence of treatment-emergent adverse events and serious adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2026-525408-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525408-82-00.